Listing & Compliance Notices

F45 Training Holdings Inc. received a nyse deficiency notice notice regarding late filing (rules 802.01E).

“April 3, 2023 indicating the Company was not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) with the SEC. The NYSE informed the Company that, under NYSE rules, the Company has six months from the Form 10-K due date of March 31, 2023 to regain compliance with the NYSE listing standards at any time prior to that date by filing the Form 10-K with the SEC. The NYSE further noted that, if the Company fails to file the Form 10-K within the six-month pe”

F45 Training Holdings Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“May 16, 2023, F45 Training Holdings Inc. (the “Company”) received a notice from the New York Stock Exchange (the “NYSE”) that, as of May 15, 2023, it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The notice has no immediate impact on the listing of the Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements.”

Blue Star Foods Corp. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 17, 2023, Blue Star Foods Corp. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has not regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market and is not eligible for a second 180 day period to regain compliance with the Minimum Bid Price Requirement. Accordingly, unless the Company timely requests an appeal of this determination before the Nasdaq Hearings Pa”

AVENUE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“$2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, reported stockholders’ equity of negative $2,157,000. The Letter further noted that as of the letter date, the Company did not have a market value of listed securities of $35 million, or net income from continued operations of”

Greenwave Technology Solutions, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 17, 2023, Greenwave Technology Solutions, Inc. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 13, 2023, to regain compliance”

Avinger Inc received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)).

“May 18, 2023, Avinger, Inc. (the “Company”) received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer satisfies the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, or the alternatives to that requirement – a $35 million market value of listed securities or $500,000 in net income in the most recent fiscal year or two or the last three fiscal years – as required by Nasdaq Listing Rule 5550(b) (the “Equity Requirement”). As with the Bid Price Deficiency Letter (as defined below)”

Athenex, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“May 16, 2023, the Company received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Case and in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the Nasdaq staff determined that the Company’s common stock will be delisted from Nasdaq. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on May 25, 2023.”

Comera Life Sciences Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“May 18, 2023, Comera Life Sciences Holdings, Inc. (the “Company”) received a determination letter (the “Letter”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has not regained compliance with the Market Value of Listed Securities (“MVLS”) Standard, since the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MLVS Rule”) and had not been at least $35 million for a minimum of 10 co”

Cingulate Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 16, 2023, Cingulate Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of $81,614 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023 was below the required minimum of $2.5 million, and because, as of May 15, 2023, the Company did not meet”

EUDA Health Holdings Ltd received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“f this date. However, the Company requires additional time to prepare, review and finalize its financial statements. The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to trade on Nasdaq under the symbol “EUDA”. As required under Nasdaq Listing Rule 5250(b)(2), the Company issued a press release on May 19, 2023, announcing that it had received the Notice. A copy of this press release is attached as Exhibit 99.1 to this Form 8-K. Forward-Looking Statements This Form 8-K contains forward-looking statements, including statements about the financia”

Innovid Corp. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“May 18, 2023, Innovid Corp. (the “Company”) received written notice from the New York Stock Exchange (the "NYSE") that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period. The NYSE notice does not result in the immediate delisting of the Company’s common stock from the NYSE. In accordance with applicable NYSE rules, the Company plans to notify the NYSE that it intends to cure the stock price deficiency and return to compliance with th”

eFFECTOR Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 17, 2023, eFFECTOR Therapeutics, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based on the Company’s stockholders’ deficit of $4.8 million as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at le”

Latch, Inc. received a nasdaq extension granted notice regarding late filing (rules 5250(c)(1)).

“May 16, 2023, the Company was unable to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “First Quarter 2023 Report”) with the SEC due to the ongoing effort to restate the Company’s consolidated financial statements for 2019, 2020, 2021, and the first quarter of 2022 (all such interim and annual periods, the “Affected Periods”). The Company presented its plan to regain compliance (the “Compliance Plan”) with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) at a March 23, 2023 hearing before a Nasdaq Hearings Panel (the “Panel”). As set forth i”

Appreciate Holdings, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 18, 2023, the Company received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) because it has not timely filed the Form 10-Q with the SEC. The Rule requires listed companies to timely file all required periodic reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s securities. However, if the Company fails to timely regain compliance with the Rule, the Company’s securities will be subject”

Baudax Bio, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

“May 17, 2023, the Company received a delist determination letter from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension. Specifically, the Company did not complete its proposed transactions and was unable to file a Current Report Form 8-K by the May 15, 2023 deadline previously required by the Staff, evidencing compliance with the Rule. As a result, unless the Company requests an appeal of the Staff’s determination, trading of the Company’s common stock will be suspended at the opening of business on May 26, 2023, and a Form 2”

Cenntro Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“May 17, 2023, Cenntro Electric Group Limited ACN 619 054 938 (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (the “Rule”) 5250(c)(1), because the Company did not timely file its quarterly report on Form 10-Q for the quarter ended March 31, 2023, with the United States Securities and Exchange Commission (the “SEC”). As previously reported, the Company also received a letter from Nasdaq on April 25, 2023 (the “Original Notice”) regarding the Company’s”

EXICURE, INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“May 17, 2023, Exicure, Inc. (the “ Company ”) received a delinquency notification letter (the “ Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that due to the delay in filing the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “ Form 10-Q ”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the “ SEC ”). The Letter states that, the Company has 60 c”

ISUN, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 16, 2023,iSun, Inc. (the “Company”) received notice (the “Delisting Notice”) from The Nasdaq Stock Market (“Nasdaq”) that it is no longer in compliance with Listing Rule 5550(a)(2) (the “Bid Price Requirement”), which requires listed securities to maintain a minimum bid price of $1 per share over a period of 30 consecutive business days. Pursuant to Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days following the receipt of the Delisting Notice to regain compliance with the Bid Price Requirement, with the possibility of extension at the discretion of Nasdaq. The Comp”

Catalent, Inc. received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“May 16, 2023, the Company received a notice (the “ NYSE Notice ”) from the New York Stock Exchange (the “ NYSE ”) that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file the Form 10-Q with the SEC. The NYSE Notice has no immediate effect on the listing of the Company’s common stock on the NYSE. The NYSE Notice informed the Company that, under NYSE rules, the Company has six months from May 15, 2023 to regain compliance with the NYSE listing standards by filing the Form 10-Q with the SEC. If the Company fails to file”

PALVELLA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 15, 2023, Pieris Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). This Not”

Tenon Medical, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 17, 2023, Tenon Medical, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 17, 2023, notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2,500,000. In the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, the Company reported stockholders’ equity of $2,474,000, which is below the mi”

Glucotrack, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“common stock with gross proceeds to the Company of approximately $10.0 million, before deducting underwriting discounts and other estimated expenses paid by the Company. The deficiency cured was the November 22, 2022 notice from Nasdaq that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) since its third quarter 2022 Form 10-Q reported stockholders’ equity under the $2.5 million required minimum. The Company acknowledges that Nasdaq will continue to monitor the Company’s ongoing compliance with the stockholders’ equity requirement and, if at the time of its next periodic r”

Adverum Biotechnologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“May 18, 2023, the Company received approval from the Listing Qualifications Department of Nasdaq to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). The Company’s securities will be transferred to the Capital Market at the opening of business on May 22, 2023. The Company’s common stock will continue to trade under the symbol “ADVM.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed companies must meet certain”

Bone Biologics Corp received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(a)(1)).

“November 17, 2022, the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that, based upon the closing bid price for the Company’s common stock for the 30 prior consecutive business day period, the Company no longer satisfied the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1), and that it had been provided a 180-calendar day grace period to regain compliance with that requirement, which period expired May 16, 2023. The Company was not eligible to obtain an additional second 180 calendar period to regain compli”

Bone Biologics Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 18, 2023, the Company was notified by the Staff that, based upon the Company’s non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) as of May 30, 2023, the Company’s securities, common stock and publically traded warrants, were subject to delisting unless the Company timely appeals the Staff’s determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the issuance of the Panel’s decision followin”

OLB GROUP, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 16, 2023, The OLB Group, Inc. (“we”, “us” or “our”) received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC (“NASDAQ”) notifying us that, for a period of 30 consecutive business days, we failed to maintain a minimum closing bid price of $1.00 as required for continued listing on the NASDAQ Capital Market pursuant to NASDAQ Listing Rule 5550(a)(2). In accordance with NASDAQ Listing Rule 5810(c)(3)(A), we have 180 calendar days, or until November 13, 2023, to regain compliance. If, at any time during the 180-day grace period, our closing bid price is”

COMSovereign Holding Corp. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“der Nasdaq rules, the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company up to 180 days from the prescribed due date for filing the Form 10-K (as extended pursuant to Rule 12b-25 under the Securities Exchange Act of 1934, as amended) to regain compliance. If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. The Company is working diligently to complete the Form 10-K and intends to”

YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 18, 2023, Yield10 Bioscience, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the quarter ended Mar”

Veradigm Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“May 18, 2023, the Company received an additional notice (the “ Additional Notice ”) from Nasdaq stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “ Form 10-Q ”), and because the Company remains delinquent in filing the Form 10-K, the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1). On May 18, 2023, the Company submitted to Nasdaq its compliance plan (the “ Compliance Plan ”) addressing both the Form 10-K and Form 10-Q filings. If approved, Nasdaq may grant an exception of up to 180 calendar days from the”

OLENOX INDUSTRIES INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 17, 2023, Safe & Green Holdings Corp. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (April 4, 2023 through May 16, 2023), the Company’s common stock did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Nasdaq”

Cyclo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 15, 2023, Cyclo Therapeutics, Inc. (the “Company”), received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company of $(438,876) as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 12, 2023, was below the minimum requirement of $2,500,000. Pursuant to Nasdaq’s Listing Rules, the Company has 45 calendar days (until June 29, 2023), to submit a plan to regain compliance with the Rule (a “Compliance Pla”

Adamas One Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 11, 2023, the Company received a deficiency letter (the “Bid Price Notice”) from Nasdaq notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Bid Price Notice has no immediate effect on the continued listing status of t”

Adamas One Corp. received a nasdaq deficiency notice notice regarding other (rules 5250(f)).

“May 10, 2023, Adamas One Corp. (the “Company”) received a deficiency letter (the “Fee Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company had not paid certain fees required by Nasdaq Listing Rule 5250(f). The Company’s past due fee balance was $62,000 and the Fee Notice informed the Company that this lack of payment would lead to the suspension of the trading of the Company’s common stock at the opening of business on May 19, 2023. In addition, Nasdaq would eventually file a Form 25-NSE with the Securities and Exc”

Aeries Technology, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5550(a)(3)).

“n May 12, 2023, the Company also received a letter (the “Notice”) from the Listing Qualifications department of Nasdaq notifying the Company that the Company no longer meets the minimum of 300 public holders required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the “Public Holder Standard”). The Notice states that the Company has until June 26, 2023 to provide Nasdaq with a definitive plan to achieve and sustain compliance with all The Nasdaq Capital Market listing requirements, including the time frame for completion of this plan. The Notice i”

Transcode Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 16, 2023, TransCode Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023”

TuSimple Holdings Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 12, 2023, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC. The Notice indicated that this serves as an additional basis for delisting the Company’s securities from Nasdaq and that the Company should present its views with respect to this additional delinquency to the Nasdaq at its hearing before the Nasdaq Hearings”

Talkspace, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

“hat for the preceding 30 consecutive business days, the closing bid price of our common stock listed on Nasdaq was below $1.00 per share and therefore we did not comply with the minimum closing bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). In anticipation of not regaining compliance with Nasdaq Listing Rule 5450(a)(1) by May 17, 2023, the end of our initial 180-day grace period, we applied to transfer the listing of our common stock to the Nasdaq Capital Market. Forward-Looking Statements This Report on Form 8-K contains”

Next Technology Holding Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 20, 2023, Staff notified the Company that it did not comply with Nasdaq’s filing requirements set forth in Listing Rule 5250(c)(1) (the “Filing Rule”) because the Company had not filed its Form 10-K for the fiscal year ended December 31, 2022. The Company may appeal Staff’s determination to a Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The Company intends to timely request a hearing before the Panel which will stay the delisting of the Company’s securities pending the issuance of a decision by the Panel and the expiration of”

Next Technology Holding Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(3)(A)(iii)).

“May 15, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq regarding the Company’s failure to maintain a closing bid price of at least $0.10 for ten consecutive trading days during the Compliance Period, which results in a Staff Delisting Determination under Rule 5810(3)(A)(iii). The Staff has determined to delist the Company’s securities from the Nasdaq. Unless the Company requests an appeal of this determination, trading of the Company’s common stock will be suspended at the opening of business on May 24, 2023. In addition, on April 20, 2023, Staff n”

Crown Electrokinetics Corp. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).

“May 15, 2023, the Company received a letter (the “Letter”) from Nasdaq notifying the Company that the Panel had granted the Company’s request to continue its listing on Nasdaq until August 28, 2023, subject to certain conditions. The Company intends to comply with the conditions set forth by the Panel, as stated in the Letter. There can be no assurance that the Panel will afford the Company more time to complete the compliance plan it articulated in the hearing, or that the Company will be able to remain in compliance with the applicable Nasdaq listing requirements on an ongoing basis.”

Crown Electrokinetics Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“May 15, 2023, the Company received a letter (the “Letter”) from Nasdaq notifying the Company that the Panel had granted the Company’s request to continue its listing on Nasdaq until August 28, 2023, subject to certain conditions. The Company intends to comply with the conditions set forth by the Panel, as stated in the Letter. There can be no assurance that the Panel will afford the Company more time to complete the compliance plan it articulated in the hearing, or that the Company will be able to remain in compliance with the applicable Nasdaq listing requirements on an ongoing basis.”

Troika Media Group, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 16, 2023, Troika Media Group, Inc. (the “Company”) received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”). The Company was notified that Nasdaq has determined to delist the Company’s securities from the Nasdaq Capital Market for failure to maintain a minimum bid price of $1.00 per share for thirty (30) consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Company intends to appeal the Staff’s determination by requesting a hearing (the”

REPUBLIC FIRST BANCORP INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 12, 2023, The Nasdaq Stock Market LLC (“Nasdaq”) notified Republic First Bancorp, Inc. (the “Company”) that because the Company’s Form 10-Q for the three months ended March 31, 2023 (the “Form 10-Q”) was not timely filed with the Securities and Exchange Commission (the “SEC”), the Company does not satisfy Nasdaq Listing Rule 5250(c)(1) (the “Filing Requirement”) and that the Nasdaq Hearings Panel (the “Panel”) would consider the additional deficiency in its deliberations regarding the Company’s continued listing. The Company previously presented for the Panel’s review the Company’s plan to”

AIB Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(3)(C)).

“May 11, 2023, the Company received a deficiency letter from the Staff of Nasdaq notifying the Company that, for the preceding 30 consecutive business days, the Company’s Market Value of Publicly Held Shares (“MVPHS”) was below the $15 million minimum requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(3)(C) (the “MVPHS Requirement”). The notifications received have no immediate effect on the Company’s Nasdaq listing. The Nasdaq rules provide the Company a compliance period of 180 calendar days in which to regain compliance. If at anytime duri”

AIB Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“May 11, 2023, the Company received a deficiency letter from the Staff of Nasdaq notifying the Company that, for the preceding 30 consecutive business days, the Company’s Market Value of Publicly Held Shares (“MVPHS”) was below the $15 million minimum requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(3)(C) (the “MVPHS Requirement”). The notifications received have no immediate effect on the Company’s Nasdaq listing. The Nasdaq rules provide the Company a compliance period of 180 calendar days in which to regain compliance. If at anytime duri”

Khosla Ventures Acquisition Co. received a nasdaq deficiency notice notice regarding board independence (rules 5605, 5605(d)(4)).

“May 9, 2023, Khosla Ventures Acquisition Co. (the “Company”) received a letter (the “Nasdaq Letter”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the resignation of Derek Anthony West, as previously disclosed, from the Company’s board of directors and its Compensation Committee, the Company is not in compliance with Nasdaq Listing Rule 5605, which requires that the Company’s Compensation Committee be comprised of at least two directors, all of whom are independent directors as defined by Nasdaq rules. The Nasdaq Lett”

Avalon Acquisition Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5450(a)(2)).

“May 11, 2023, Avalon Acquisition Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(2) (the “Minimum Total Holders Rule”), which requires the Company to have at least 400 total holders for continued listing on the Nasdaq Global Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Global Market. T”

FOXO TECHNOLOGIES INC. received a nyse_american delisting notice notice regarding other (rules 1001).

“May 16, 2023, NYSE American provided written notice to the Company and publicly announced that NYSE Regulation has determined to commence proceedings to delist the Warrants and that the Warrants are no longer suitable for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading price of the Warrants. To effect the delisting, NYSE American will apply to the Securities and Exchange Commission (the “SEC”) to delist the Warrants pending completion of applicable procedures. The Company is evaluating whether it will appeal NYSE American’s determination. Trading in t”

Edgio, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 12, 2023, Edgio, Inc. (“Edgio” or the “Company”) received a notification letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), and because the Company remains delinquent in filing its Annual Report on Form 10-K for the period ended December 31, 2022 (the “Initial Delinquent Filing”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which req”

AUDACY, INC. received a nyse delisting notice notice regarding other (rules 802.01D).

“May 16, 2023, the New York Stock Exchange (the “ NYSE ”) publicly announced and notified Audacy, Inc. (the “ Company ”) that the NYSE elected to commence proceedings to delist the Company’s Class A Common Stock (the “ common stock ”) from the NYSE pursuant to Section 802.01D of the NYSE Listed Company Manual (“ Section 802.01D ”). Under Section 802.01D, the NYSE will consider commencing delisting procedures when a company’s listed securities experience an abnormally low selling price. The NYSE will apply to the Securities and Exchange Commission (the “ SEC ”) to delist the common stock pending”